Home » Topics » BioWorld Science

BioWorld Science
RSS

Proteostasis updates status of doublet and triplet cystic fibrosis programs

Oct. 18, 2018

GenSight reports 72-week data from REVERSE phase III trial of GS-010 in LHON

Oct. 18, 2018

MeiraGTx and Janssen enter gene therapy research collaboration and evaluation agreement

Oct. 18, 2018

Eiger reports phase II data on pegylated interferon lambda in HDV infection

Oct. 18, 2018

Bristol-Myers Squibb discovers PD-1/PD-L1 interaction inhibitors

Oct. 18, 2018

New 5-HT2C receptor agonists described by AbbVie

Oct. 18, 2018

Novartis discloses protein atonal homolog 1 activators

Oct. 18, 2018

Pseudolysin inhibitors presented by Antabio SAS

Oct. 18, 2018

Beijing Jacobio Pharmaceuticals, Jacobio-Alpha Pharmaceuticals patent PTP2C inhibitors

Oct. 18, 2018

Merck & Co. discovers antimycobacterial oxazolidinones

Oct. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...